PharmaShots | Incisive News in 3 Shots

Subscribe Now

Neurocrine Biosciences

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

April 24, 2024

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

April 4, 2024

Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenita...

October 6, 2023

Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

September 13, 2023

PharmaShots Weekly Snapshots (August 21 – 25, 2023)

PharmaShots Weekly Snapshots (August 21 – 25, 2023)

August 25, 2023

Neurocrine Biosciences’ Ingrezza (valbenazine) Capsules Receives the US FDA’s Approval for the Treatment of Chorea Associated with Huntington's Disease

Neurocrine Biosciences’ Ingrezza (valbenazine) Capsules Receives the US FDA’s Approval for the Treatment of Chorea Associated with...

August 21, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us